anti-CD5/anti-TGF-beta receptor II bispecific antibody (Xencor)

N/A

Report date: 2025/01/26 18:41:11

Base Information

Drug Nameanti-CD5/anti-TGF-beta receptor II bispecific antibody (Xencor)
Drug Alias NameCD5/TGF-beta R2 bispecific antibody XmAb (Xencor)CD5 + TGF-beta R2 blocker bispecific antibody XmAb (Xencor)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionT-cell surface glycoprotein CD5 modulatorsTransforming growth factor beta receptor 2 inhibitors
TargetsT-cell surface glycoprotein CD5Transforming growth factor beta receptor 2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesXencor Inc
China Registration ClassN/A

Develop Information

Active CompaniesXencor Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A